Integrating reliable and predictive liver models in the drug development pipeline will reduce cost burdens and safety issues. Indeed, various enlightening models have recently been investigated. For instance, Ewart et al. reported a liver-on-a-chip model on a polydimethylsiloxane (PDMS) microfluidic apparatus, containing sinusoidal endothelial cells, stellate cells, and primary human hepatocytes sandwiched in Matrigel ECMs. The model showed toxicity responses to clozapine and olanzapine. A similar model has also been tested to show cross-species toxicity responses from primary hepatocytes to bosentan . However, while toxicity responses are an important component of preclinical testing, hepatocyte models that can reproduce physiological drug metabolism/clearance profiles are limited in literature. Although a few models using primary cells are reported , stringent statistical comparisons with in vivo data are not available.